In this episode of MD Newsline, Dr. Michael A. Tomeo, a board-certified dermatologist and clinical researcher, explores the complexities of Chronic Spontaneous Urticaria (CSU), commonly known as chronic hives. He discusses the underlying role of mast cells and histamine, the diagnostic process, current treatment guidelines, and the exciting emergence of targeted biologic therapies that are transforming patient care.

Dr. Tomeo explains how chronic hives can significantly impact quality of life, affecting sleep, work productivity, and emotional well-being. He also highlights the importance of accurate diagnosis, patient self-monitoring, and the growing understanding of mast cell biology that is leading to safer and more effective treatment options.

Understanding Chronic Spontaneous Urticaria
Dr. Tomeo explains that chronic spontaneous urticaria is characterized by recurring hives lasting longer than six weeks. He discusses how mast cell activation and histamine release drive symptoms and how CSU differs from allergic reactions caused by external triggers.

The Impact of Chronic Hives on Daily Life
Beyond itching and visible skin lesions, chronic hives can disrupt sleep, impair work performance, and significantly reduce quality of life. Dr. Tomeo also discusses more serious manifestations such as angioedema and the potential risk of anaphylaxis.

Diagnostic Evaluation and Differential Diagnosis
A thorough patient history and physical examination remain the cornerstone of diagnosis. Dr. Tomeo reviews the role of laboratory testing, including CBC, inflammatory markers, ANA testing, thyroid antibodies, and immunoglobulin levels, to help identify underlying causes and distinguish CSU from conditions such as urticarial vasculitis.

Current Treatment Guidelines
Treatment typically begins with non-sedating antihistamines, which may be increased up to four times the standard dose when necessary. Dr. Tomeo discusses the use of H1 and H2 blockers and explains when clinicians should consider escalating therapy for patients who remain symptomatic.

The Growing Role of Biologic Therapies
Dr. Tomeo highlights the success of biologic therapies such as omalizumab (Xolair), which targets IgE and helps reduce mast cell activation. He also discusses emerging therapies that target upstream inflammatory pathways, including BTK inhibitors and KIT receptor inhibitors.

Advances in Mast Cell Biology
A deeper understanding of mast cell signaling pathways is opening new opportunities for treatment. Researchers are now targeting the cellular mechanisms responsible for histamine release rather than simply blocking histamine after it is produced.

The Gut-Skin Connection
Dr. Tomeo explores how gut health and inflammation may influence immune system activity and skin disease. He discusses the concept of increased intestinal permeability and the potential role of dietary modifications in improving inflammatory conditions.

Patient Self-Advocacy and Disease Tracking
Keeping a detailed symptom diary can help patients and clinicians identify patterns, monitor treatment response, and better characterize disease severity. Dr. Tomeo encourages patients to document symptoms, medications, and potential exposures to improve care.

Dr. Tomeo emphasizes that chronic spontaneous urticaria is far more than a simple skin condition. Advances in immunology and mast cell research are leading to highly targeted therapies that offer improved symptom control, enhanced safety profiles, and renewed hope for patients living with chronic hives. Early diagnosis, individualized treatment plans, and strong patient-clinician communication remain essential for achieving the best outcomes.

Website: https://mdnewsline.com/

Newsletter: https://mdnewsline.com/subscribe/

Contact with Dr. Michael A. Tomeo: Here

In this episode of MD Newsline, Dr. Collette Honore, a board-certified dermatologist, discusses the evolving landscape of psoriasis diagnosis and treatment. Drawing on years of clinical experience, she shares practical insights into identifying psoriasis across diverse skin tones, selecting appropriate biologic therapies, managing treatment resistance, and addressing complex cases involving psoriatic arthritis, metabolic syndrome, inflammatory bowel disease, and severe disease variants.

Dr. Honoré also highlights the importance of health equity in dermatology, the unique challenges of diagnosing psoriasis in skin of color, and the need for clinicians to listen closely to patients while tailoring treatment plans to individual needs and lifestyles.

Dr. Honoré explains why psoriasis can present differently in patients with skin of color and emphasizes the importance of careful examination rather than relying solely on textbook descriptions. She discusses common diagnostic pitfalls and the value of skin biopsies when the diagnosis is uncertain.

Patients with skin of color often experience delayed diagnosis and undertreatment. Dr. Honoré shares strategies for improving recognition of psoriasis in diverse populations and ensuring equitable access to effective therapies.

Selecting a biologic requires consideration of disease severity, body surface area involvement, lifestyle factors, comorbidities, and patient preferences. Dr. Honoré reviews the role of IL-17 inhibitors, IL-23 inhibitors, TNF inhibitors, and other treatment options in modern psoriasis management.

Certain psoriasis presentations can significantly affect quality of life despite limited body surface area involvement. Dr. Honoré discusses biologic therapies that have demonstrated effectiveness in difficult-to-treat areas, including the scalp, nails, palms, soles, and genital regions.

Psoriasis is more than a skin disease. Dr. Honoré highlights the importance of screening for psoriatic arthritis, metabolic syndrome, cardiovascular disease, and inflammatory bowel disease when developing treatment plans.

When patients lose response to therapy, clinicians must determine whether to optimize treatment, combine therapies, or switch biologic classes. Dr. Honoré explains her approach to managing primary and secondary treatment failure while minimizing the risk of antibody formation.

Regular follow-up and laboratory monitoring remain critical for patients receiving methotrexate and biologic therapies. Dr. Honoré discusses practical monitoring schedules and how she balances safety with long-term treatment success.

From erythrodermic psoriasis to pustular disease and severe palmoplantar involvement, Dr. Honoré shares real-world experiences managing complex patients and explains when hospitalization becomes necessary.

Dr. Honoré concludes with actionable recommendations for clinicians, including the importance of comprehensive patient histories, awareness of medication triggers, recognition of psoriasis in children, and early intervention to prevent long-term complications.

Dr. Honoré emphasizes that successful psoriasis management requires individualized care, careful attention to comorbidities, and a willingness to adapt treatment strategies over time. By improving diagnostic accuracy, embracing newer biologic therapies, and addressing disparities in care, clinicians can significantly improve outcomes and quality of life for patients living with psoriasis.

Website: https://mdnewsline.com/

Newsletter: https://mdnewsline.com/subscribe/

Contact with Dr. Collette Honore: Here

In this episode of MD Newsline, Dr. Neelam Vashi, board-certified dermatologist at the Dermatology Institute of Boston, provides a comprehensive overview of psoriasis as a chronic immune-mediated systemic condition. She discusses how our understanding of psoriasis has evolved beyond a "skin disease" to a disorder with important systemic implications, including joint disease and cardiometabolic risk.

Dr. Vashi shares practical insights into diagnosis, screening for comorbidities, treatment selection across disease severities, and the rapidly advancing biologic landscape. She also addresses common misconceptions, adherence challenges, and the psychosocial impact of psoriasis.

Psoriasis is a chronic immune-driven condition that leads to thickened, inflamed skin—but its impact goes far beyond the surface. Dr. Vashi explains the importance of recognizing systemic inflammation, including joint involvement and cardiovascular risk.

Early identification of joint symptoms is critical. Dr. Vashi outlines simple screening questions clinicians can use in busy practices and emphasizes timely rheumatology referral to prevent permanent joint damage.

Psoriasis is associated with increased cardiovascular risk due to systemic inflammation. Dr. Vashi discusses the importance of blood pressure monitoring, smoking cessation, weight management, and heart-healthy lifestyles.

Both genetic predisposition and environmental factors—such as infections, stress, and immune triggers—play roles in disease onset and flares. Adult-onset psoriasis is common, even in patients without childhood history.

Treatment is individualized based on disease severity, body surface area, location, and quality-of-life impact. Dr. Vashi reviews when to use:

· Topical therapies (corticosteroids, vitamin D analogs)

· Phototherapy

· Oral small molecules (PDE4 and TYK2 inhibitors)

· Biologic therapies (TNF-alpha, IL-17, IL-23 inhibitors)

Modern targeted biologics have transformed moderate-to-severe psoriasis care, making clear or nearly clear skin an achievable goal for many patients.

Treatment strategies may shift in pregnancy, pediatrics, older adults, and patients with liver, kidney, or inflammatory bowel disease. Shared decision-making remains central.

Scalp, nails, palms, soles, genital, and inverse psoriasis require tailored approaches and careful formulation selection to minimize irritation and maximize adherence.

With psoriasis being chronic, long-term management is key. Extended dosing intervals and maintenance strategies help reduce treatment fatigue.

Dr. Vashi dispels myths that psoriasis is contagious, caused by poor hygiene, or triggered directly by specific foods. Education remains essential for both patients and families.

After inflammation resolves, patients may experience hyperpigmentation, hypopigmentation, or erythema—particularly in individuals with darker skin tones. Early aggressive treatment may reduce pigmentary changes.

Psoriasis is a systemic inflammatory condition that requires comprehensive, patient-centered care. With modern therapies—including highly targeted biologics—clinicians can achieve clear or nearly clear skin while also addressing joint disease, cardiometabolic risk, and quality-of-life concerns. Early intervention, shared decision-making, and ongoing monitoring are critical to optimizing long-term outcomes.

Website: https://mdnewsline.com/
Newsletter: https://mdnewsline.com/subscribe/

Contact with Dr. Neelam Vashi: Here

In this episode of MD Newsline, we sit down with Dr. Meena Singh, a board-certified dermatologist and dermatologic surgeon, to discuss psoriasis—its causes, diagnosis challenges, and the latest advancements in treatment. Dr. Singh provides valuable insights into how psoriasis presents in different skin tones, the role of the gut microbiome, and emerging biologic therapies. She also highlights the importance of early diagnosis, collaborative care between primary physicians and dermatologists, and the potential impact of lifestyle modifications.

Episode Highlights:

Psoriasis Risk Factors & Diagnosis

Psoriasis is a multifactorial condition influenced by genetics, immune markers, and environmental triggers. While genetic predisposition plays a role, studies show that even identical twins do not always share the condition. Researchers have also identified gut microbiome profiles that may contribute to immune dysregulation, further linking intestinal health to psoriasis. The condition affects 2% of the general population, but for individuals of African descent, it has a higher impact on quality of life, likely due to delayed diagnosis and differences in presentation.

Diagnosing psoriasis presents unique challenges, particularly in skin of color, where the condition may not have the typical silvery scale seen in lighter skin tones. Many patients initially try natural remedies before seeking medical attention, which can lead to delays in diagnosis and treatment. The journey from primary care to dermatology is often lengthy, and even when patients do seek care, misdiagnosis remains a concern. Psoriatic arthritis, a common comorbidity, is also frequently underdiagnosed, as many patients do not initially recognize joint pain as a symptom.

Challenges in Diagnosis & Gaps in Care

Severity of psoriasis is graded using the PASI Index, which assesses body surface area affected and symptom intensity. Mild cases are often treated with topical steroids, vitamin D analogs, and newer topical JAK inhibitors, while moderate to severe cases may require biologic therapies targeting specific inflammatory pathways like IL-17, IL-12/23, and JAK inhibitors. Recent advancements have led to highly effective biologic medications, and researchers are now exploring oral small molecules that could provide targeted treatment without injections.

The Future of Psoriasis Treatment

Looking ahead, the future of psoriasis treatment is shifting toward personalized medicine, with research focusing on genetic and cytokine profiling to tailor therapies to individual patients. While there is still no cure, patients can achieve remission for months or even years with the right combination of therapies. In addition to medical treatments, lifestyle modifications such as diet and exercise can play a significant role in reducing inflammation and improving overall health. Collaboration between dermatologists and rheumatologists is crucial in managing both psoriasis and its associated conditions, such as psoriatic arthritis, cardiovascular disease, and inflammatory bowel disease.

As research continues to evolve, new treatment options are on the horizon that may revolutionize psoriasis care. However, psoriasis remains a chronic condition, and ongoing management is essential to maintaining a high quality of life.

Key Takeaway:

Psoriasis in skin of color is often misdiagnosed because it appears more purple or hyperpigmented rather than the classic red plaques with silvery scale, leading to delayed diagnosis and treatment. New biologic therapies, including IL-17 and IL-12/23 inhibitors, have significantly improved outcomes for moderate to severe cases, with promising oral treatments on the horizon. Psoriatic arthritis is a common but underdiagnosed condition, as many patients don't recognize joint pain as a symptom, making early detection by dermatologists crucial.

Resources & Links:

Website: MD Newsline
Newsletter: Subscribe Here

Connect with Dr. Meena Singh: Skin and Hair Center